ADAR1 Capital Management
AUSTIN, TXfiles as ADAR1 Capital Management, LLC
$2.1bn in 262 US stocks at the end of 30 June 2026. The top 10 are 42.2% of the money. It changed about 25.6% of the portfolio this quarter.
Value
$2.1bn
Stocks
262
Top 10 share
42.2%
Turnover
25.6%
What changed this quarter
New
Bought for the first time this quarter.
- Editas MedicineEDIT1.4% of the fund
- Vor BiopharmaVOR0.6% of the fund
- Faeth TherapeuticsFTH0.4% of the fund
- Ascendis Pharma A/SASND0.4% of the fund
- Amanat AcquisitionAMAN0.4% of the fund
- Research Alliance Corp IIIRACC0.3% of the fund
- Relay TherapeuticsRLAY0.3% of the fund
- Disciplined GrowthDGAC-U0.2% of the fund
- Boundless BioBOLD0.2% of the fund
- Avalyn PharmaAVLN0.2% of the fund
- JATT II AcquisitionJATT0.2% of the fund
- Rein TherapeuticsRNTX0.2% of the fund
- Apogee TherapeuticsAPGE0.2% of the fund
- enGene TherapeuticsENGN0.2% of the fund
- Sagimet BiosciencesSGMT0.2% of the fund
- Cue BiopharmaCUE<0.1% of the fund
- First Tracks BiotherapeuticsTRAX<0.1% of the fund
- InMed PharmaceuticalsINM<0.1% of the fund
- Artiva BiotherapeuticsARTV<0.1% of the fund
- ALX Oncology HoldingsALXO<0.1% of the fund
- Cartesian TherapeuticsRNAC<0.1% of the fund
- Cyclerion Therapeutics<0.1% of the fund
- Acadia PharmaceuticalsACAD<0.1% of the fund
- Structure TherapeuticsGPCR<0.1% of the fund
- Aura BiosciencesAURA<0.1% of the fund
Added
Bought more of a stock they already held.
- Abivax SAABVX11.4% of the fund+29%
- State STR Spdr S&P 500 ETF TSPY4.6% of the fund+70%
- ZAI LABZLAB3.0% of the fund+136%
- Agios PharmaceuticalsAGIO2.3% of the fund+816%
- Crinetics PharmaceuticalsCRNX2.2% of the fund+7%
- Praxis Precision MedicinesPRAX1.2% of the fund+4850%
- InsmedINSM1.2% of the fund+546%
- Celldex TherapeuticsCLDX1.1% of the fund+45%
- Viking TherapeuticsVKTX1.1% of the fund+152%
- Taysha Gene TherapiesTSHA1.0% of the fund+2%
- Ovid TherapeuticsOVID0.9% of the fund+63%
- Enliven TherapeuticsELVN0.9% of the fund+18%
- Enanta PharmaceuticalsENTA0.9% of the fund+2518%
- Nektar TherapeuticsNKTR0.8% of the fund+51%
- Inhibikase TherapeuticsIKT0.7% of the fund+12%
- uniQureQURE0.7% of the fund+326%
- RallybioRLYB0.7% of the fund+4411%
- Regeneron PharmaceuticalsREGN0.7% of the fund+83%
- InventivaIVA0.6% of the fund+66%
- Ionis PharmaceuticalsIONS0.6% of the fund+4%
- BridgeBio PharmaBBIO0.6% of the fund+87%
- Sarepta TherapeuticsSRPT0.6% of the fund+179%
- Adlai NortyeANL0.6% of the fund+763%
- Climb BioCLYM0.5% of the fund+38%
- Zura BioZURA0.5% of the fund+179%
Cut
Sold some of their stake.
- Protagonist TherapeuticsPTGX5.6% of the fund-3%
- Roivant SciencesROIV5.3% of the fund-4%
- ImmunovantIMVT4.3% of the fund-13%
- CytokineticsCYTK1.8% of the fund-28%
- SepternaSEPN1.5% of the fund-14%
- Anteris Technologies GlobalAVR1.5% of the fund-17%
- Denali TherapeuticsDNLI1.3% of the fund-45%
- Spyre TherapeuticsSYRE1.2% of the fund-16%
- Vir BiotechnologyVIR1.2% of the fund-10%
- Monopar TherapeuticsMNPR1.0% of the fund-18%
- Inspire Medical SystemsINSP0.8% of the fund-8%
- Revolution MedicinesRVMD0.8% of the fund-35%
- Establishment Labs HoldingsESTA0.8% of the fund-13%
- Rhythm PharmaceuticalsRYTM0.7% of the fund-36%
- Sutro BiopharmaSTRO0.6% of the fund-23%
- OnKure TherapeuticsOKUR0.5% of the fund-8%
- Xenon PharmaceuticalsXENE0.5% of the fund-27%
- UroGen PharmaURGN0.4% of the fund-36%
- Amylyx PharmaceuticalsAMLX0.4% of the fund-51%
- DBV Technologies S ADBVT0.4% of the fund-48%
- SavaraSVRA0.4% of the fund-4%
- VaxcytePCVX0.4% of the fund-44%
- CG OncologyCGON0.4% of the fund-36%
- Opus GeneticsIRD0.3% of the fund-4%
- Replimune GroupREPL0.3% of the fund-59%
Sold out
Sold their entire stake.
- Terns Pharmaceuticals-100%
- Beam TherapeuticsBEAM-100%
- Scholar Rock HoldingSRRK-100%
- Vertex PharmaceuticalsVRTX-100%
- Viridian TherapeuticsVRDN-100%
- Ascendis Pharma A/SASND-100%
- Eli LillyLLY-100%
- Dianthus TherapeuticsDNTH-100%
- Belite BIOBLTE-100%
- Arcellx-100%
- ArriVent BioPharmaAVBP-100%
- Apellis Pharmaceuticals-100%
- Masimo-100%
- TeleflexTFX-100%
- BioAge LabsBIOA-100%
- Alkermes plc.ALKS-100%
- Soleno Therapeutics-100%
- Centessa Pharmaceuticals-100%
- Amicus Therapeutics-100%
- UnitedHealth GroupUNH-100%
- Sensient TechnologiesSXT-100%
- SchrodingerSDGR-100%
- 4D Molecular TherapeuticsFDMT-100%
- DAY One Biopharmaceuticals I-100%
- Bristol-Myers SquibbBMY-100%
Holdings
- Abivax SAABVX
- Share
- 11.4%
- Value
- $240m
- Shares
- 1,804,703
+29%
- State STR Spdr S&P 500 ETF TSPY
- Share
- 4.6%
- Value
- $96m
- Shares
- 129,087
+70%
- ZAI LABZLAB
- Share
- 3.0%
- Value
- $64m
- Shares
- 3,369,034
+136%
- Crinetics PharmaceuticalsCRNX
- Share
- 2.2%
- Value
- $46m
- Shares
- 1,222,080
+7%
- EA Series TrustBOXX
- Share
- 1.9%
- Value
- $39m
- Shares
- 337,125
Held
- Spdr Series TrustBIL
- Share
- 0.6%
- Value
- $12m
- Shares
- 135,585
Held
- Adlai NortyeANL
- Share
- 0.6%
- Value
- $12m
- Shares
- 1,017,805
+763%
- Helix Acquisition Corp. IIIHLXC
- Share
- 0.5%
- Value
- $11m
- Shares
- 1,000,000
Held
- DBV Technologies S ADBVT
- Share
- 0.4%
- Value
- $9m
- Shares
- 528,295
-48%
- Amanat AcquisitionAMAN
- Share
- 0.4%
- Value
- $8m
- Shares
- 750,000
New
- Damora Therapeutics
- Share
- 0.3%
- Value
- $7m
- Shares
- 280,000
Held
- Research Alliance Corp IIIRACC
- Share
- 0.3%
- Value
- $7m
- Shares
- 650,000
New
- Oaktree Acquisition Corp IIIOACCU
- Share
- 0.3%
- Value
- $6m
- Shares
- 516,482
Held
- Disciplined GrowthDGAC-U
- Share
- 0.2%
- Value
- $5m
- Shares
- 500,000
New
- Bhav AcquisitionBHAVU
- Share
- 0.2%
- Value
- $5m
- Shares
- 495,000
Held
- Avalyn PharmaAVLN
- Share
- 0.2%
- Value
- $5m
- Shares
- 146,447
New
- AtaiBeckleyATAI
- Share
- 0.2%
- Value
- $5m
- Shares
- 913,242
Held
- JATT II AcquisitionJATT
- Share
- 0.2%
- Value
- $5m
- Shares
- 417,724
New
| Company | Share of fund | Value | Shares | Change |
|---|---|---|---|---|
| Abivax SAABVX | 11.4% | $240m | 1,804,703 | +29% |
| Protagonist TherapeuticsPTGX | 5.6% | $118m | 960,863 | -3% |
| Roivant SciencesROIV | 5.3% | $112m | 3,157,008 | -4% |
| State STR Spdr S&P 500 ETF TSPY | 4.6% | $96m | 129,087 | +70% |
| ImmunovantIMVT | 4.3% | $90m | 2,330,716 | -13% |
| ZAI LABZLAB | 3.0% | $64m | 3,369,034 | +136% |
| Agios PharmaceuticalsAGIO | 2.3% | $48m | 1,288,053 | +816% |
| Crinetics PharmaceuticalsCRNX | 2.2% | $46m | 1,222,080 | +7% |
| EA Series TrustBOXX | 1.9% | $39m | 337,125 | Held |
| CytokineticsCYTK | 1.8% | $39m | 457,907 | -28% |
| SepternaSEPN | 1.5% | $32m | 940,747 | -14% |
| Anteris Technologies GlobalAVR | 1.5% | $31m | 3,145,096 | -17% |
| Editas MedicineEDIT | 1.4% | $29m | 8,889,000 | New |
| Denali TherapeuticsDNLI | 1.3% | $26m | 1,029,080 | -45% |
| Spyre TherapeuticsSYRE | 1.2% | $25m | 283,982 | -16% |
| Vir BiotechnologyVIR | 1.2% | $25m | 2,456,677 | -10% |
| Praxis Precision MedicinesPRAX | 1.2% | $25m | 74,253 | +4850% |
| InsmedINSM | 1.2% | $24m | 228,520 | +546% |
| Celldex TherapeuticsCLDX | 1.1% | $23m | 619,542 | +45% |
| Viking TherapeuticsVKTX | 1.1% | $22m | 574,038 | +152% |
| Taysha Gene TherapiesTSHA | 1.0% | $21m | 3,040,466 | +2% |
| Monopar TherapeuticsMNPR | 1.0% | $20m | 217,595 | -18% |
| Ovid TherapeuticsOVID | 0.9% | $20m | 7,417,479 | +63% |
| Enliven TherapeuticsELVN | 0.9% | $20m | 387,718 | +18% |
| Enanta PharmaceuticalsENTA | 0.9% | $20m | 1,344,510 | +2518% |
| Nektar TherapeuticsNKTR | 0.8% | $17m | 244,184 | +51% |
| Inspire Medical SystemsINSP | 0.8% | $17m | 374,617 | -8% |
| Revolution MedicinesRVMD | 0.8% | $16m | 87,509 | -35% |
| Establishment Labs HoldingsESTA | 0.8% | $16m | 185,619 | -13% |
| Prothena Corp PublicPRTA | 0.7% | $15m | 1,554,535 | Held |
| Rhythm PharmaceuticalsRYTM | 0.7% | $15m | 136,158 | -36% |
| Inhibikase TherapeuticsIKT | 0.7% | $15m | 7,387,205 | +12% |
| uniQureQURE | 0.7% | $15m | 324,672 | +326% |
| RallybioRLYB | 0.7% | $15m | 926,352 | +4411% |
| Regeneron PharmaceuticalsREGN | 0.7% | $14m | 22,208 | +83% |
| InventivaIVA | 0.6% | $14m | 3,606,656 | +66% |
| Sutro BiopharmaSTRO | 0.6% | $13m | 404,014 | -23% |
| Ionis PharmaceuticalsIONS | 0.6% | $13m | 166,286 | +4% |
| BridgeBio PharmaBBIO | 0.6% | $13m | 176,689 | +87% |
| Sarepta TherapeuticsSRPT | 0.6% | $13m | 730,649 | +179% |
| CytomX TherapeuticsCTMX | 0.6% | $13m | 3,365,118 | Held |
| Vor BiopharmaVOR | 0.6% | $13m | 680,626 | New |
| Spdr Series TrustBIL | 0.6% | $12m | 135,585 | Held |
| EquilliumEQ | 0.6% | $12m | 3,758,569 | Held |
| Adlai NortyeANL | 0.6% | $12m | 1,017,805 | +763% |
| Climb BioCLYM | 0.5% | $11m | 822,649 | +38% |
| Helix Acquisition Corp. IIIHLXC | 0.5% | $11m | 1,000,000 | Held |
| Zura BioZURA | 0.5% | $10m | 1,759,295 | +179% |
| OnKure TherapeuticsOKUR | 0.5% | $10m | 2,238,684 | -8% |
| Maze TherapeuticsMAZE | 0.5% | $10m | 339,276 | +577% |
| Xenon PharmaceuticalsXENE | 0.5% | $10m | 166,550 | -27% |
| Teva Pharmaceutical IndustriesTEVA | 0.4% | $9m | 277,848 | +4% |
| UroGen PharmaURGN | 0.4% | $9m | 252,395 | -36% |
| Faeth TherapeuticsFTH | 0.4% | $9m | 361,010 | New |
| Amylyx PharmaceuticalsAMLX | 0.4% | $9m | 494,378 | -51% |
| DBV Technologies S ADBVT | 0.4% | $9m | 528,295 | -48% |
| SavaraSVRA | 0.4% | $9m | 1,403,409 | -4% |
| VaxcytePCVX | 0.4% | $8m | 146,034 | -44% |
| CG OncologyCGON | 0.4% | $8m | 118,664 | -36% |
| Mineralys TherapeuticsMLYS | 0.4% | $8m | 298,886 | +93% |
| Ascendis Pharma A/SASND | 0.4% | $8m | 28,604 | New |
| Amanat AcquisitionAMAN | 0.4% | $8m | 750,000 | New |
| Nurix TherapeuticsNRIX | 0.4% | $8m | 313,236 | +459% |
| BiohavenBHVN | 0.4% | $7m | 501,687 | +1020% |
| Prime MedicinePRME | 0.3% | $7m | 1,997,552 | Held |
| FreenomeFRNM | 0.3% | $7m | 674,695 | +35% |
| Opus GeneticsIRD | 0.3% | $7m | 1,783,781 | -4% |
| Lexeo TherapeuticsLXEO | 0.3% | $7m | 1,565,950 | +7% |
| Damora Therapeutics | 0.3% | $7m | 280,000 | Held |
| Replimune GroupREPL | 0.3% | $7m | 655,784 | -59% |
| LeonaBioLONA | 0.3% | $7m | 777,100 | +7% |
| Korro BioKRRO | 0.3% | $7m | 540,054 | Held |
| Research Alliance Corp IIIRACC | 0.3% | $7m | 650,000 | New |
| InflaRxIFRX | 0.3% | $7m | 3,000,000 | +1795% |
| Relay TherapeuticsRLAY | 0.3% | $7m | 358,333 | New |
| Janux TherapeuticsJANX | 0.3% | $6m | 420,881 | +41% |
| Pliant TherapeuticsPLRX | 0.3% | $6m | 5,509,724 | +113% |
| Whitehawk TherapeuticsWHWK | 0.3% | $6m | 1,341,394 | +944% |
| Krystal BiotechKRYS | 0.3% | $6m | 16,420 | -18% |
| Arbutus BiopharmaABUS | 0.3% | $6m | 1,268,147 | -60% |
| PfizerPFE | 0.3% | $6m | 252,400 | +226% |
| Brighthouse FinancialBHF | 0.3% | $6m | 95,523 | Held |
| Edgewise TherapeuticsEWTX | 0.3% | $6m | 143,199 | +58% |
| AlectorALEC | 0.3% | $6m | 2,883,583 | +175% |
| Fulcrum TherapeuticsFULC | 0.3% | $6m | 1,565,029 | +1099% |
| Arrowhead PharmaceuticalsARWR | 0.3% | $6m | 69,800 | Held |
| Acumen PharmaceuticalsABOS | 0.3% | $6m | 2,111,334 | -2% |
| Oaktree Acquisition Corp IIIOACCU | 0.3% | $6m | 516,482 | Held |
| Globus MedicalGMED | 0.3% | $6m | 70,100 | +249% |
| Monte Rosa TherapeuticsGLUE | 0.2% | $5m | 216,752 | Held |
| Disciplined GrowthDGAC-U | 0.2% | $5m | 500,000 | New |
| Bhav AcquisitionBHAVU | 0.2% | $5m | 495,000 | Held |
| DanaherDHR | 0.2% | $5m | 25,932 | -16% |
| Boundless BioBOLD | 0.2% | $5m | 1,968,216 | New |
| Avalyn PharmaAVLN | 0.2% | $5m | 146,447 | New |
| ARS PharmaceuticalsSPRY | 0.2% | $5m | 600,999 | -56% |
| AtaiBeckleyATAI | 0.2% | $5m | 913,242 | Held |
| Prelude TherapeuticsPRLD | 0.2% | $5m | 900,900 | +489% |
| JATT II AcquisitionJATT | 0.2% | $5m | 417,724 | New |
| Rein TherapeuticsRNTX | 0.2% | $5m | 4,500,000 | New |
Showing the largest 100 of 262.
Options (10)
- Ishares TRIWM
- Type
- Put
- Value
- $19m
- Contracts
- 62,500
- State STR Spdr S&P 500 ETF TSPY
- Type
- Put
- Value
- $19m
- Contracts
- 25,000
- Spdr Series TrustXBI
- Type
- Put
- Value
- $11m
- Contracts
- 67,400
- Abivax SAABVX
- Type
- Call
- Value
- $6m
- Contracts
- 44,400
- Keen Vision AcquisitionKVACF
- Type
- Call
- Value
- $930,000
- Contracts
- 75,000
- Amylyx PharmaceuticalsAMLX
- Type
- Put
- Value
- $720,196
- Contracts
- 40,100
- Ultragenyx PharmaceuticalRARE
- Type
- Call
- Value
- $667,800
- Contracts
- 20,000
- Novo Nordisk A SNVO
- Type
- Call
- Value
- $623,220
- Contracts
- 13,000
- Corbus Pharmaceuticals HoldingsCRBP
- Type
- Call
- Value
- $562,800
- Contracts
- 60,000
- Solidion TechnologySTI
- Type
- Call
- Value
- $125,415
- Contracts
- 13,500
| Company | Type | Value | Contracts |
|---|---|---|---|
| Ishares TRIWM | Put | $19m | 62,500 |
| State STR Spdr S&P 500 ETF TSPY | Put | $19m | 25,000 |
| Spdr Series TrustXBI | Put | $11m | 67,400 |
| Abivax SAABVX | Call | $6m | 44,400 |
| Keen Vision AcquisitionKVACF | Call | $930,000 | 75,000 |
| Amylyx PharmaceuticalsAMLX | Put | $720,196 | 40,100 |
| Ultragenyx PharmaceuticalRARE | Call | $667,800 | 20,000 |
| Novo Nordisk A SNVO | Call | $623,220 | 13,000 |
| Corbus Pharmaceuticals HoldingsCRBP | Call | $562,800 | 60,000 |
| Solidion TechnologySTI | Call | $125,415 | 13,500 |
Over time and by industry
Value over time
Jun '25
Dec '25
Jun '26
Value is up 246.7% since 30 June 2025.
Where the money is
Health care74.0%
Financial services1.5%
Industrials0.1%
Real estate0.0%
Technology0.0%
Retail & consumer0.0%
Other24.3%
From the fund's 13F filings. They list US stocks and options only, 45 days after each quarter, and leave out cash, bonds, shorts and foreign shares.